Sensorion Announces Publication of Seliforant Phase 1 Study Data
Seliforant (formerly SENS-111) is currently being studied in an ongoing Phase 2 trial for the treatment of acute unilateral vestibulopathy, a debilitating disease of the inner ear. Its maker, Sensorion, has announced the publication of data in the ‘British Journal of Clinical Pharmacology’ from a Phase 1 study evaluating the safety, tolerability, pharmacokinetics of the drug in healthy subjects. More data are expected at the end of 2018.
Read More